Cancer related fatigue (malaise)
Conditions
Interventions
Oral intake of 60 mL of Acanthopanax senticosus extract for 28 days.
Sponsors
Health Sciences University of Hokkaido
f-CRO Office
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: #1 Advanced cancer patient who can take food orally and whose expected survival time is more than one month #2 The score of Brief Fatigue Inventory is more than 3 or more #3 Age 20 years and older #4 Ability to provide and written informed consent
Exclusion criteria
Exclusion criteria: #1 The patients who have taken Acanthopanax Senticosus and are not off it for more than 3 months. #2 Allergy to Acanthopanax Senticosus and/or chlorella and/or honey. #3 Breast, uterus and ovary cancer patient who are histologically confirmed with estrogen receptor positive. #4 The patient who received Doxifluridine (FURTULON) chemotherapy. #5 Uncontrolled hypertension (Blood pressure more than 180/90 mmHg) #6 Currently taking digoxin formulation. #7 Co-existence of severe complication. #8 Pregnant or expected to be pregnant, and breast feeding mother. #9 Co-existence of endometriosis and myoma uteri. #10 Unable to provide and written informed consent due to mental disorder. #11 Concomitant use of drugs which is contraindicated towards either Acanthopanax Senticosus or chlorella.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of the patient whose BFI can be evaluated at "visit 2". | — |
Secondary
| Measure | Time frame |
|---|---|
| # The rate of improvement in cancer-related fatigue # The changes in laboratory data # Safety (The frequency of total adverse event) | — |
Countries
Japan
Contacts
Public ContactNANAE WATANABE
Higashi Sapporo Hospital Department of Internal Medicine
Outcome results
None listed